Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Washington
Big Ten Cancer Research Consortium
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Amgen
Ohio State University Comprehensive Cancer Center
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center
BioNTech SE
Jonsson Comprehensive Cancer Center
Emory University
Rutgers, The State University of New Jersey
Henry Ford Health System
University of Southern California
Big Ten Cancer Research Consortium
Technische Universität Dresden
University of California, Irvine
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Phanes Therapeutics
British Columbia Cancer Agency
Gustave Roussy, Cancer Campus, Grand Paris
Fundación GECP